54,774 Shares in The Cooper Companies, Inc. $COO Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 54,774 shares of the medical device company’s stock, valued at approximately $3,096,000.

Several other hedge funds have also recently modified their holdings of COO. Avalon Trust Co purchased a new position in Cooper Companies during the second quarter valued at $25,000. Elevation Wealth Partners LLC boosted its holdings in shares of Cooper Companies by 1,136.4% during the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 375 shares during the last quarter. Continuum Advisory LLC bought a new position in shares of Cooper Companies during the 2nd quarter valued at about $30,000. J.Safra Asset Management Corp bought a new position in shares of Cooper Companies during the 2nd quarter valued at about $32,000. Finally, Northwestern Mutual Wealth Management Co. purchased a new position in shares of Cooper Companies during the second quarter valued at about $60,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on COO. UBS Group reduced their target price on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating on the stock in a report on Thursday, September 10th. Citigroup reissued a “neutral” rating and set a $60.00 price target (down from $80.00) on shares of Cooper Companies in a research note on Thursday, September 10th. Wall Street Zen lowered Cooper Companies from a “buy” rating to a “hold” rating in a research note on Saturday, September 12th. Mizuho set a $75.00 price target on Cooper Companies and gave the company an “outperform” rating in a report on Thursday, September 10th. Finally, Barclays raised Cooper Companies to a “hold” rating in a research note on Wednesday, October 7th. Four research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, Cooper Companies presently has a consensus rating of “Hold” and a consensus price target of $68.60.

Insiders Place Their Bets

In related news, Director Walter M. Rosebrough, Jr. bought 3,000 shares of the business’s stock in a transaction dated Monday, September 14th. The shares were purchased at an average price of $54.29 per share, with a total value of $162,870.00. Following the transaction, the director owned 20,000 shares in the company, valued at $1,085,800. This trade represents a 17.65% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Paul A. Keel purchased 4,701 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The shares were bought at an average price of $53.18 per share, for a total transaction of $249,999.18. Following the acquisition, the director directly owned 4,701 shares in the company, valued at $249,999.18. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 34,701 shares of company stock valued at $1,880,039 over the last ninety days. 2.08% of the stock is owned by insiders.

Cooper Companies Price Performance

COO stock traded down $1.15 during trading on Friday, hitting $62.36. 2,059,749 shares of the company’s stock traded hands, compared to its average volume of 3,311,420. The Cooper Companies, Inc. has a 52 week low of $51.01 and a 52 week high of $89.83. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.73 and a current ratio of 1.22. The business has a fifty day simple moving average of $59.20 and a 200 day simple moving average of $68.61. The stock has a market capitalization of $11.86 billion, a price-to-earnings ratio of 21.28, a P/E/G ratio of 2.41 and a beta of 0.83.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The firm had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same period in the previous year, the firm posted $0.49 EPS. The business’s quarterly revenue was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, research analysts expect that The Cooper Companies, Inc. will post 4.53 EPS for the current fiscal year.

Cooper Companies announced that its Board of Directors has initiated a share buyback plan on Wednesday, September 9th that authorizes the company to repurchase $3 billion in shares. This buyback authorization authorizes the medical device company to repurchase up to 22.7% of its shares through open market purchases. Share buyback plans are often a sign that the company’s board believes its shares are undervalued.

Cooper Companies Company Profile

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women’s health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women’s health.